Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Rating) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 1,170,000 shares, an increase of 17.2% from the June 30th total of 998,700 shares. Currently, 4.0% of the company’s stock are short sold. Based on an average trading volume of 499,300 shares, the short-interest ratio is currently 2.3 days.
Alzamend Neuro Stock Performance
Shares of NASDAQ:ALZN opened at $0.90 on Wednesday. The business has a 50 day moving average price of $0.91 and a 200 day moving average price of $1.08. Alzamend Neuro has a twelve month low of $0.80 and a twelve month high of $4.84.
In related news, major shareholder Milton C. Ault III acquired 100,000 shares of the stock in a transaction dated Thursday, May 5th. The shares were acquired at an average price of $1.07 per share, with a total value of $107,000.00. Following the acquisition, the insider now owns 325,000 shares in the company, valued at approximately $347,750. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have purchased 233,000 shares of company stock valued at $227,613.
Institutional Trading of Alzamend Neuro
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.
- Get a free copy of the StockNews.com research report on Alzamend Neuro (ALZN)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Are Baidu’s Delisting Fears a Good Entry for New Investors?
- Market Fundamentals Drive Results For The Williams Companies
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.